

**Amendments to the Claims:**

The listing of claims provided below will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1-127. (Cancelled)

128. (Previously presented) A purified mammalian Prostate Tumor Inducing Gene-1 protein.

129. (Previously presented) The purified mammalian Prostate Tumor Inducing Gene-1 protein of Claim 128, wherein the protein comprises the amino acid sequence of SEQ ID NO:17.

130. (Previously presented) An antibody capable of specifically binding to the mammalian Prostate Tumor Inducing Gene-1 protein of Claim 128.

131. (Previously presented) The antibody of Claim 130, wherein the antibody is a monoclonal antibody.

132. (Previously presented) A composition comprising an antibody of Claim 130 and a pharmaceutically acceptable carrier.

133. (Previously presented) The antibody of Claim 130 coupled to a cytotoxic agent.

134. (Previously presented) The antibody of Claim 133, wherein the cytotoxic agent is a radioisotope or a toxin.

135. (Previously presented) An immunoassay for detecting the presence of a mammalian Prostate Tumor Inducing Gene-1 protein in a biological sample comprising the steps of:
- a) contacting the biological sample with the antibody of Claim 130 under conditions permitting the formation of a complex between said antibody and the mammalian Prostate Tumor Inducing Gene-1 protein; and
  - b) detecting said complex, wherein detection of said complex indicates the presence of mammalian Prostate Tumor Inducing Gene-1 protein in a biological sample.
136. (Previously presented) A mammalian Prostate Tumor Inducing Gene-1 protein bound to the antibody of Claim 130.
137. (New) A method for detecting cancer cells in a sample comprising detection of the expression of Prostate Tumor Inducing Gene-1 in the sample, comprising the steps of:
- a) contacting the sample with an antibody capable of specifically recognizing PTI-1 protein under conditions permitting the formation of a complex between the PTI-1 protein and the antibody; and
  - b) measuring the complex formed, thereby detecting cancer cells in the sample.
140. (New) The method of Claim 139, wherein the antibody is a monoclonal antibody.